Article ID Journal Published Year Pages File Type
6100325 Journal of Crohn's and Colitis 2011 5 Pages PDF
Abstract
The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Gastroenterology
Preview
Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States
Authors
, , , , ,